# Elicio Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elicio-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.elicio.com
- Total disclosed funding: $36M
- Latest round: Series B (Oct 2, 2019)
- Investors on record: 5

## About

Elicio Therapeutics, Inc. is a Boston-based biopharmaceutical firm specializing in lymph node-targeted immunotherapies that enhance the immune response against aggressive cancers, particularly pancreatic ductal adenocarcinoma.Founded in 2011 in Boston, US, Elicio Therapeutics, Inc. focuses on developing innovative immunotherapies. The company has completed 12 funding deals. Its latest funding was a Series C round, raising USD 21.02 mn. The company is led by CEO Robert Connelly, and its founder, Darrell Irvine, has a history of innovation in biotechnology.Elicio Therapeutics specializes in developing lymph node-targeted immunotherapies aimed at enhancing immune responses against aggressive cancers, notably pancreatic ductal adenocarcinoma (PDAC). Utilizing its proprietary AMP platform, the company creates next-generation vaccines, immunomodulators, and adjuvants, designed to activate T cells and amplify immune responses. Elicio's products serve a varied client base, including healthcare providers and research institutions focused on oncology across the United States and select international markets, addressing critical needs in cancer treatment via the lymphatic system.Elicio Therapeutics generates revenue through partnerships with healthcare institutions and collaborative agreements for its immunotherapy products. These agreements facilitate the acquisition of therapies through direct purchases or clinical trial contracts. Key products such as ELI-002, ELI-007, and ELI-008 are central to Elicio's revenue strategy, emphasizing the innovative solutions offered in immuno-oncology. For the most recent year, the company reported an EBITDA of USD -6,140,508.Elicio Therapeutics is focused on expanding its product line and geographic reach. The company is working on upcoming releases of its immunotherapy products and plans to enter new markets by targeting European and Asian healthcare sectors within the next two years. Recent funding from the Series C round will support these initiatives. Furthermore, all VC investors have exited their stake in Elicio Therapeutics, Inc., although the financial terms were not disclosed.

## Funding rounds

- Series B, Oct 2, 2019, $33M — Clal Biotechnology, Livzon Mabpharm, Inc., Efung Capital, Thynk Capital
- Series B, Nov 6, 2018 — Thynk Capital
- Series A, Jul 18, 2012, $3.3M — Access BridgeGap Ventures

## Investors

- Access BridgeGap Ventures (https://capitalatlas.ai/funds/access-bridgegap-ventures) — Series A
- Thynk Capital (https://capitalatlas.ai/funds/thynk-capital) — Series B
- Clal Biotechnology (https://capitalatlas.ai/funds/clal-biotechnology) — Series B
- Livzon Mabpharm, Inc. — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B